Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
MAPS Public Benefit Corporation (MAPS PBC), the nonprofit’s clinical-stage private arm, published new data from its second multi-site, ethno-racially diverse Phase 3 clinical study of MDMA-assisted therapy for PTSD in Nature Medicine.
The randomized MAPP2 study gave participants a split dose, separated by 1.5 to 2 hours, of 80 or 120 mg of MDMA hydrochloride (or placebo,) and following a 40 to 60 mg dose during three therapy sessions. The placebo group received extended therapy sessions. Continue reading HERE.
Combining MDMA With Psilocybin Or LSD Could Reduce Difficult Trips
Recent peer-reviewed research published in the journal Nature posits that a small dose of MDMA could be helpful against uncomfortable or difficult experiences and amplify positive ones when combined with either psilocybin or LSD.
The study, published in August and authored by researchers from Imperial College London (ICL) and New York University’s Langone Center for Psychedelic Medicine delves into a hypothesis of “candy-flipping,” clinical research conducted by MindMed’s (NASDAQ: MNMD) research collaborator Dr. Matthias Liechti and his team at University Hospital Basel. Read more HERE.
Congress Update: House Committee Green Lights Psychedelics Amendments
On September 12, the House Rules Committee voted on one of a series of large-scale budget bills which include recently introduced bipartisan marijuana and psychedelics amendments.
The committee’s decision is key, as it is the immediate prior step for proposals to make it, or not, to the House floor. The vote was around the Department of Defense (DoD) FY2024 appropriations bill HR 4365. Read more HERE.
Scotland's Approval Of Pilot 'Safer' Drug Consumption Site, Overdose Prevention Debate In UK
Scottish Advocate, the country's top attorney, replied to a request from the Parliament’s cross-committee on tackling …